Latest stories on NTLA
Intellia: Phase 3 HAELO Win Doesn't Fix The Commercial Problem
Seeking Alpha32 · bearishproduct/pr
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News
StockTitan50 · neutralgeneral
Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now?
Yahoo Top57 · neutralanalyst
Most and least shorted mid- to mega-cap healthcare stocks at the end of June
Seeking Alpha42 · neutralgeneral
Most shorted stocks over $2B market cap
Seeking Alpha50 · neutralgeneral
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
The Motley Fool56 · neutralanalyst
Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results
Yahoo Top76 · bullishproduct/pr
NTLA Surges as Phase 3 Data Shows 91% Reduction in Severe HAE Attacks—First One-Time Gene Therapy Candidate Nears FDA Submission
MarketChameleon82 · bullishproduct/pr
Intellia Highlights Strong Phase 3 Lonvo-z HAE Results
TipRanks73 · bullishproduct/pr
Intellia Therapeutics, Inc. (NTLA) files 8-K
SEC 8-K50 · neutralgeneral
Why Is NTLA Stock Jumping 5% Premarket Today?
Stocktwits News67 · bullishproduct/pr
Intellia Therapeutics, Inc. (NTLA) files 8-K
SEC 8-K50 · neutralgeneral
Intellia Therapeutics, Inc. (NTLA) Buy Rating Reiterated Despite Share Offering Dilution
Yahoo Finance48 · neutralanalyst
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News
StockTitan50 · neutralgeneral
Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update
Yahoo Finance73 · bullishproduct/pr
Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight
Seeking Alpha67 · bullishproduct/pr
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying
Yahoo Top56 · neutralgeneral